Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Rethinking long-term osteoporosis drug use

With the launch of the first prescription osteoporosis medication 15 years ago, millions of Americans with the bone-thinning disease began taking the drugs and never looked back.

But now many bone-health doctors are looking back and becoming increasingly uneasy.

In the past few years, evidence has emerged that long-term use of osteoporosis drugs — particularly the oldest class of drugs, the bisphosphonates — may do more harm than good. Some doctors are starting to tell at least some of their patients to stop taking the drugs for a time, to take a "drug holiday."

That strategy is a tough sell for consumers who have been bombarded with osteoporosis medication advertisements for years.

When osteoporosis drugs first came out, "people thought, this is a recurring disease, like high blood pressure. So why wouldn't you treat it for the rest of their lives?" said Dr. Richard Eastell, an expert in bone metabolism at the University of Sheffield in Britain who spoke about the issue late last year at the annual meeting of the American Society for Bone and Mineral Research. "But there are now some anxieties with long-term use."

REASONS FOR CAUTION

Several factors are merging to usher in a new era of caution surrounding the medications. One is the simple acknowledgment that some people are approaching 10 to 15 years of continuous use.

"Worldwide, it's a commonly discussed question as to how long you should go on with these treatments," Eastell said. "Beyond 10 years, we have no knowledge of how these treatments work."

Added to that, several potential risks from long-term use have recently arisen.

In rare cases, people taking bisphosphonates — which include Fosamax, Boniva, Actonel and Reclast — can develop jaw necrosis, a condition in which the jawbone begins to deteriorate. And a study published in September in BMJ, the British Medical Journal, found that people who take bisphosphonate drugs for several years have a slightly higher risk of developing esophageal cancer.

Experts don't know why the drugs would increase the cancer risk, although the drugs have been known to irritate the esophagus in some people.

Of most concern, however, is that long-term bisphosphonate users can develop rare and unusual fractures in the thigh bone, or femur. A 2008 study first linked long-term use of the medications to femur fractures, and other research has confirmed the link. On Oct. 13, the Food and Drug Administration announced it will now require bisphosphonate drugs to carry information on their labels describing the risk of rare femur fractures.

Without a lot of clear scientific evidence to guide them, doctors are debating how long people should take bisphosphonates and whether occasional drug holidays are a good idea.

HOW BISPHOSPHONATES WORK

Bones grow and change. After reaching peak bone mass in the early or mid 20s, bone density begins to decline because old bone is lost faster than new bone is made. This process speeds up in midlife, especially after menopause in women.

Bisphosphonates work by preventing the body from reabsorbing bone. They slow bone loss but also interfere with the natural bone-remodeling cycle, the process by which old bone is continually broken down and new bone is fashioned to replace it. This interference, it's thought, lies behind the unusual fracture risk. And some bone specialists think that leaving bones free of drugs for a year or more in people with osteoporosis allows the bone-remodeling process to kick in again.

Drug holidays may also be justified, these specialists say, because bisphosphonate medications remain in bone tissue for a year or two after people stop taking them. "To give high doses indefinitely is not what you want to do," said Dr. Ian Reid, an endocrinologist and bone expert at the University of Auckland in New Zealand. "After five years, it's a good time to reassess. If the bones don't show osteoporosis, we typically stop the drug and monitor bone density.''

CLEAR BENEFITS

Doctors are pulling back from prescribing osteoporosis medications for people who have some bone loss but do not meet the diagnostic criteria for osteoporosis, said Dr. Felicia Cosman, clinical director of the National Osteoporosis Foundation. This milder condition is sometimes referred to as osteopenia.

"It's ironic that many of these cases of femur factures were in women with mild bone loss who probably should not have been on these drugs," Cosman said. "We probably used too many bisphosphonates in too many women for too many years. But it's not that we should stop it in everyone. The therapy has to be individualized."

The osteoporosis drug market was valued at $9.6 billion last year and is expected to double within 10 years.

Still, under-use of osteoporosis drugs remains a bigger problem than overuse, Cosman said. One large study of osteoporosis patients found almost half had stopped taking their medications within a year after diagnosis.

"It's been difficult to convince people to take drugs," she said. "Now some are more skeptical that these drugs are providing the benefits that we said they did. We need to be clear that a two- to five-year course of these drugs saves fractures, pain, disability and life. There is just no question about that."

Rethinking long-term osteoporosis drug use 01/14/11 [Last modified: Friday, January 14, 2011 3:30am]
Photo reprints | Article reprints

© 2017 Tampa Bay Times

    

Join the discussion: Click to view comments, add yours

Loading...
  1. Bar review: Cheap drinks do fine at the Joint in St. Petersburg

    Bars & Spirits

    The Tyrone area of St. Petersburg is a little light on drinking spots, so the locals must have been happy when a long-running neighborhood spot — formerly Donk's Sports Tavern and Double J's Sports Bar — reopened earlier this year as the Joint.

    Patrons sit at the bar in the Joint in St. Petersburg.
  2. Local Craft Beer of the Week: Fireberry Tea Ale, Sea Dog Brewing Co.

    Bars & Spirits

    Clearwater's Sea Dog Brewing Co. doesn't get enough credit. Most craft beer drinkers familiar with the near-ubiquitous Sea Dog and Shipyard brands, which have been brewed in Maine since the early '90s, erroneously conclude that the Clearwater location is more of the same. But this location, opened in 2013, features its …

    Justin Grant/Special to tbt*
  3. Epilogue: Snooty, 69, a breed apart from other manatees (w/video)

    Wildlife

    New York City has the Statue of Liberty. San Francisco has the Golden Gate Bridge. St. Louis as the Arch.

    And for 68 years, Bradenton had Snooty.

    Aquarium curator Carol Audette touches noses with Snooty the manatee in 2001 at the South Florida Museum. Snooty was 53 then. [Times 2001]
  4. Verizon is back: Unlimited data is boosting subscriptions

    Energy

    After posting surprising losses among cellphone subscribers earlier this year, Verizon is back. The wireless carrier said Thursday that it has added 358,000 phone subscribers over the past several months, blowing analyst expectations out of the water and showing that its unlimited data plans are helping to keep …

    Verizon said Thursday that it has added 358,000 phone subscribers over the past several months, blowing analyst expectations out of the water and showing that its unlimited data plans are helping to keep customers loyal.
(Associated Press]
  5. Director: Jameis Winston is most charismatic 'Hard Knocks' QB

    Bucs

    TAMPA — The Bucs' Hard Knocks life has already begun. HBO and NFL Films' behind-the-scenes documentary series of an NFL training camp — this season featuring the Bucs — started filming even before training camp began. That means Matt Dissinger, the show's director, is already the hardest working …

    Jameis Winston (3) lifts a victorious arm after the Bucs beat the San Francisco 49ers in October at Levi's Stadium in Santa Clara, Calif. [LOREN ELLIOTT   |   Times ]